Lipid profile indices in young people with GCK-MODY and HNF1A-MODY
https://doi.org/10.52727/2078-256X-2021-17-4-43-47
Abstract
Despite the fact that most young patients with hyperglycemia are diagnosed with type 1 (T1DM) and type 2 (T2DM) diabetes, up to 10 % of all cases of the disease are MODY diabetes. The most common types of MODY are GCK-MODY and HNF1A-MODY, therefore the investigation of their clinical and laboratory characteristics, including lipid spectrum indicators is of high clinical significance. The aim of this research work was to study the values of lipid spectrum indicators in patients diagnosed with GCK-MODY and HNF1A-MODY at the age from 18 to 45 years. Lipid profile parameters were investigated in 56 patients aged 18 to 45 years with diagnosed GCK-MODY and HNF1A-MODY by molecular genetic tests, matched by sex, age and body mass index (BMI). No statistically significant differences were found for any of the indicators, however, in patients with HNF1A-MODY, the decrease in HDL-C is determined significantly more often than in GCKMODY. Thus, the group of persons with MODY differs in the level of lipid profile indices depending on the type of MODY.
Supporting agencies: The work was done in the State Assignment of the budget theme № 121090800101-7.
About the Authors
A. K. Ovsyannikova
Research Institutе of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Alla K. Ovsyannikova, phD, MD, senior researcher, laboratory of clinical-population and preventive research of therapeutic and endocrine diseases
630089, Novosibirsk, Boris Bogatkov str., 175/1
I. A. Belyaeva
Novosibirsk Clinical District Hospital N 1
Russian Federation
Russian Federation
Irina A. Belyaeva, endocrinologist
630559, Novosibirsk Region, Koltsovo village, 21
R. B. Galenok
Novosibirsk State Medical University
Russian Federation
Russian Federation
Regina B. Galenok, student of 5 course
630091, Novosibirsk, Krasny av., 52
O. D. Rymar
Research Institutе of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Oksana D. Rymar, phD, MD, senior researcher, director of laboratory of clinical-population and preventive research of therapeutic and endocrine diseases
630089, Novosibirsk, Boris Bogatkov str., 175/1
References
1. Rymar O.D., Ovsjannikova A.K., Mustafina S.V., Maksimov V.N., Kulikov I.V., Voevoda M.I. The role of MODY-diabetes in the structure of the incidence of diabetes mellitus among young patients. Sibirskiy meditsinskiy zhurnal, 2011; 26 (4-2): 45–49. (In Russ.) doi:10.14341/DM12319
2. Zubkova N.A., Gioeva O.A., Tikhonovich Yu.V. et al. Genotype-based personalized correction of glycemic control in patients with MODY due to mutations in GCK, HNF1A and HNF4A genes. World J. Personalized Medicine, 2017; 1 (1): 40–48. (In Russ). doi:10.14341/WJPM9298
3. Hattersley A., Bruining J., Shield J., Njolstad P., Donaghue K.C. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diabetes, 2009; 10: 33–42. doi:10.1111/J.1399-5448.2009.00571
4. Zubkova N.A., Arbatskaya N.Yu., Petryaikina E.E. et al. Type 3 form of MODY: the clinical and molecular-genetic characteristic. Nine cases of the disease. Problemy Endocrinologii, 2014; 60 (1): 51–56. (In Russ). doi:10.14341/PROBL201460151-56
5. Ovsyannikova A.K., Shakhtshneider E.V., Ivanoshchuk D.E., Voevoda M.I., Rymar O.D. GCK-MODY diabetes course in persons over 18 years of age: pro-spective observation. Diabetes Mellitus, 2021; 24 (2): 133–140. (In Russ.) doi:10.14341/DM12319
6. Macha F., Baigentb C., Catapanoc A.L. et al. ESC/ EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019; 290: 140–205.
7. Dedov I.I., Shestakova M.V., Mayorov A.Yu. Standards of specialized diabetes care. Diabetes Mellitus, 2021; 24 (S1): 1–222. (In Russ.) doi:10.14341/DM12802
8. Wędrychowicz A., Tobór E., Wilk M. et al. Phenotype heterogeneity in glucokinase-maturity-onset diabetes of the young (GCK-MODY) patients. J. Clin. Res. Pediatr. Endocrinol., 2017; 9 (3): 246–252. doi:10.4274/jcrpe.4461
9. Schober E., Rami B., Grabert M. et al. DPV-Wiss Initiative of the German Working Group for Paediatric Diabetology and phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet. Med., 2009; 26: 466–473. doi:10.1210/jc.2018-01696
10. Spégel P., Ekholm E., Tuomi T. et al. Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2). Diabetes, 2013; 62 (2): 653–661. doi: 10.2337/db12-0827
11. Fendler W., Rizzo M., Borowiec M., et al. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults. Clin. Endocrinol., 2011; 75 (3): 403–404. doi:10.1111/j.1365-2265.2011.04052.x
12. Fu J., Wang T., Liu J. et al. Using clinical indices to distinguish MODY2 (GCK mutation) and MODY3 (HNF1A mutation) from type 1 diabetes in a young Chinese population. Diabetes Ther., 2019; 10: 1381– 1390. doi:10.1007/s13300-019-0647-x
13. Ekholm E., Nilsson R., Groop L. et al. Alterations in bile acid synthesis in carriers of hepatocyte nuclear factor 1alpha mutations. J. Int. Med., 2013; 274 (3): 263–272. doi:10.1111/joim.12082
14. Silverman M.G., Ference B.A., Im K. et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA, 2016; 316 (12): 1289–1297. doi:10.1001/jama.2016.13985
15. St-Jean M., Boudreau F., Carpentier A.C. et al. HNF1α defect influences post-prandial lipid regulation. PLoS ONE, 2017; 12 (5): e0177110. doi:10.1371/journal.pone.0177110
16. Huang X., Gong S., Ma Y. et al. Lower circulating miR-122 level in patients with HNF1A variant-induced diabetes compared with type 2 diabetes. J. Diabetes Res., 2018; 2018: 7842064. doi:10.1155/2018/7842064
Review
For citations:
Ovsyannikova A.K., Belyaeva I.A., Galenok R.B., Rymar O.D. Lipid profile indices in young people with GCK-MODY and HNF1A-MODY. Ateroscleroz. 2021;17(4):43-47. (In Russ.) https://doi.org/10.52727/2078-256X-2021-17-4-43-47
Views:
311
Email this article 